CYP3A5*3 and CYP3A4*22 Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach.

MLA

Mohammed Ali, Zeyar, et al. “CYP3A5*3 and CYP3A4*22 Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach.” Pharmaceutics, vol. 15, no. 12, Dec. 2023, p. 2699. EBSCOhost, https://doi.org/10.3390/pharmaceutics15122699.

APA

Mohammed Ali, Z., Meertens, M., Fernández, B., Fontova, P., Vidal-Alabró, A., Rigo-Bonnin, R., Melilli, E., Cruzado, J. M., Grinyó, J. M., Colom, H., & Lloberas, N. (2023). CYP3A5*3 and CYP3A4*22 Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach. Pharmaceutics, 15(12), 2699. https://doi.org/10.3390/pharmaceutics15122699

Chicago

Mohammed Ali, Zeyar, Marinda Meertens, Beatriz Fernández, Pere Fontova, Anna Vidal-Alabró, Raul Rigo-Bonnin, Edoardo Melilli, et al. 2023. “CYP3A5*3 and CYP3A4*22 Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach.” Pharmaceutics 15 (12): 2699. doi:10.3390/pharmaceutics15122699.